Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

5.90SEK
4:22am EST
Change (% chg)

-0.25kr (-4.07%)
Prev Close
6.15kr
Open
6.00kr
Day's High
6.00kr
Day's Low
5.90kr
Volume
3,512
Avg. Vol
28,173
52-wk High
9.75kr
52-wk Low
5.25kr

KDEV.ST

Chart for KDEV.ST

About

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical... (more)

Overall

Beta: 0.74
Market Cap(Mil.): kr319.57
Shares Outstanding(Mil.): 51.96
Dividend: --
Yield (%): --

Financials

  KDEV.ST Industry Sector
P/E (TTM): -- 34.38 30.76
EPS (TTM): -5.93 -- --
ROI: -54.61 13.26 14.82
ROE: -149.30 16.85 16.24

BRIEF-Karolinska Development: OssDsign announces new European partnerships

* Its portfolio company OssDsign AB announces new European partnerships for commercialization of novel medical implants

Jan 12 2017

BRIEF-Karolinska Development Q3 operating loss narrows to SEK 7.0 million

* Q3 net sales 0.4 million Swedish crowns ($43,451) versus 0.3 million crowns year ago

Nov 23 2016

BRIEF-Karolinska Development's Umecrine Cognition raises SEK 45 mln to advance GR3027

* Umecrine Cognition raises 45 million Swedish crowns ($4.9 million) to advance GR3027, a novel drug candidate for hepatic encephalopathy

Nov 22 2016

BRIEF-Karolinska Development: Modus Therapeutics granted US patents for sickle cell disease drug candidate sevuparin

* Karolinska Development company Modus Therapeutics granted U.S. patents for sickle cell disease drug candidate sevuparin

Nov 07 2016

BRIEF-Karolinska Development: positive phase 1 data with GR3027 in hepatic encephalopathy

* Karolinska Development company Umecrine Cognition announces positive phase 1 data with GR3027 in hepatic encephalopathy

Nov 03 2016

BRIEF-Karolinska Development: Aprea Therapeutics updates clinical data of APR-246

* Portfolio company Aprea Therapeutics updates clinical data from phase IB trial of APR-246 in ovarian cancer.

Oct 10 2016

BRIEF-Karolinska Development's Dilafor raises SEK 51 million for study

* Karolinska Development portfolio company Dilafor AB raises 51 million Swedish crowns ($6 million) to facilitate phase IIb clinical study with tafoxiparin

Sep 27 2016

BRIEF-Karolinska Development: collaboration with AbbVie for Parkinson's Disease Research

* Its portfolio company BioArctic enters into collaboration with AbbVie for Parkinson's Disease Research

Sep 20 2016

BRIEF-Karolinska Development: Preliminary data from retrospective study on OSSDSIGN Cranial

* Preliminary data from retrospective study indicates that OSSDSIGN Cranial may provide better, more permanent solution for cranioplasty, even in complex patient population

Sep 05 2016

BRIEF-Karolinska Development Q2 net sales fall to SEK 0.6 mln

* Net sales amounted to 0.6 million Swedish crowns ($70,000) in Q2 (1.1 million crowns in Q2 2015)

Aug 31 2016

Earnings vs. Estimates